Aqueous topical formulation comprising an antiangiogenic drug that is an anti VEGF Antibody and a liposome consists of a Lipid based Peg； its use in the treatment of a disease or condition related to VEGF, and Method for treating cancer, psoriasis, diabetic macular edema, among ot Ras diseases.
The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.<；p>；LA INVENCIÓ；N PROPORCIONA A UNA FORMULACION ACUOSA TOPICA QUE COMPRENDE UN FARMACO ANTIANGIOGENICO QUE ES UN ANTICUERPO ANTI-VEGF Y UN LIPOSOMA FORMADO DE UN LIPIDO A BASE DE PEG； SU USO EN EL TRATAMIENTO DE UNA ENFERMEDAD O CONDICION RELACIONADA CON VEGF； Y METODO PARA TRATAR CANCER, PSORIASIS Y EDEMA MACULAR DIABETICO, ENTRE OTRAS ENFERMEDADES.<；/p>；
